Between May @ , @ , and Dec @ , @ , @ patients in UNCOVER-@ were randomly assigned to receive subcutaneous placebo ( n = @ ) , etanercept ( n = @ ) , or ixekizumab every @ weeks ( n = @ ) or every @ weeks ( n = @ ) ; between Aug @ , @ , and Feb @ , @ , @ patients in UNCOVER-@ were randomly assigned to receive placebo ( n = @ ) , etanercept ( n = @ ) , ixekizumab every @ weeks ( n = @ ) , or ixekizumab every @ weeks ( n = @ ) .